Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Biosimilar Barricade Breached: Amgen Manufacturing Patents Ruled Not Infringed

Executive Summary

Apotex's Neulasta and Neupogen biosimilars do not infringe Amgen's patent, showing sponsors can get around innovator's manufacturing process patents.


Related Content

Humira Biosimilar: Boehringer Faces Same Launch Hurdles As Amgen
Biosimilar Launch Notification May Head Back To Court
Biosimilar Litigation: Battles Continue Over Launch Notification, Access To FDA Info
Biosimilars Still Flummoxed By Neulasta: Sponsors Now 0 For 2 At FDA
FDA Met Biosimilar Review Timelines But Missed Meeting Goals In 2015
Neulasta Biosimilar: Smooth Patent Dance, Stumble On Launch Notification


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts